AUSTRALIAN researchers have demonstrated that a new drug compound can prevent long COVID symptoms in mice, which could lead to a future treatment for the condition.
The PLpro inhibitor also treats acute COVID better than Paxlovid, the current leading treatment, noted the team from the Walter and Eliza Hall Institute in Melbourne.
The next stage is to develop a version of the drug that can be used in humans.
The above article was sent to subscribers in Pharmacy Daily's issue from 09 Apr 25
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 09 Apr 25
